#ACR22 Abstr#0349 We now have therapies for #lupus. How early should we use them? Real-world data showed 5-year risk of severe infection was reduced in Belimumab vs MTX/AZA/MMF initiators (adjusted to relevant confounders) @RheumNow https://t.co/xXg039zg7m https://t.co/9LEIyoakOY
Links:
Comparative Risks of Infection with Belimumab versus Oral Immunosuppressants in…
http://bit.ly/3ULxjXk
12-11-2022